Background: The ErZhi formula (EZF) exhibits sound therapeutic effects on osteosarcopenia (OS). However, EZF's therapeutic effects on skeletal muscles are rarely reported. This study explored the mechanism of EZF in skeletal muscle during OS by integrating energy metabolism and metabolomics.
Methods: After an ovariectomized rat model was established for 4 weeks, the rats were subjected to a 12-week intervention of EZF and alendronate. The rats' body weight, gastrocnemius muscle mass, degree of myofiber fibrosis, and myofiber cross-sectional area (CSA) were measured to evaluate the pathological state of the gastrocnemius muscle. The mitochondrial membrane potential and reactive oxygen species (ROS) levels were detected to assess mitochondrial function. Then, energy metabolite analysis and metabolomics were performed on the gastrocnemius muscle.
Results: Compared to the model group, EZH increased CSA by 5.58% and decreased myofiber fibrosis by 15.11%. Notably, compared to the model group, EZH exhibited a 52.66% increase in mitochondrial membrane potential and a 44.32% reduction in ROS levels. Starch and sucrose metabolism, insulin secretion, insulin resistance, and galactose metabolism were the most significantly affected pathways in energy metabolism. Thirty-five differential metabolites were found in the metabolomics of the gastrocnemius muscle, and EZF could effectively inhibit the sphingolipid metabolism pathway. Correlation analysis identified 13 differential metabolites that were significantly associated with skeletal muscle mass, ROS production, muscle fibrosis, and mitochondrial function, suggesting that these metabolites may play important roles in the progression of skeletal muscle lesions.
Conclusions: EZF alleviates OS by regulating skeletal muscle physiological indicators, mitochondrial function, and energy metabolism.
| [1] |
Nielsen BR, Abdulla J, Andersen HE, Schwarz P, Suetta C. Sarcopenia and osteoporosis in older people: a systematic review and meta-analysis. Eur Geriatr Med. 2018; 9(4): 419-434.
|
| [2] |
Huang T, Li C, Chen F, et al. Prevalence and risk factors of osteosarcopenia: a systematic review and meta-analysis. BMC Geriatr. 2023; 23(1):369.
|
| [3] |
Laskou F, Patel HP, Cooper C, Dennison E. A pas de deux of osteoporosis and sarcopenia: osteosarcopenia. Climacteric. 2022; 25(1): 88-95.
|
| [4] |
Xu S, Yu F, Xu D, Zhao C, Wu W. Study on the biological mechanism of musculoskeletal comorbidities with subthreshold osteosarcopenia. Chin J Osteoporos. 2021; 27(3): 446-449.
|
| [5] |
Frontera WR, Ochala J. Skeletal muscle: a brief review of structure and function. Calcif Tissue Int. 2015; 96(3): 183-195.
|
| [6] |
Li X, Lu X, Fan D, et al. Synergistic effects of Erzhi pill combined with methotrexate on osteoblasts mediated via the Wnt1/LRP5/β-catenin signaling pathway in collagen-induced arthritis rats. Front Pharmacol. 2020; 11:228.
|
| [7] |
Fu SF, Zhao YQ, Ren M, et al. A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine granules for the treatment of menopausal symptoms by stages. Menopause. 2016; 23(3): 311-323.
|
| [8] |
Zuo JY, Park C, Doschak M, Löbenberg R. Are the release characteristics of Erzhi pills in line with traditional Chinese medicine theory? A quantitative study. J Integr Med. 2021; 19(1): 50-55.
|
| [9] |
Qin XY, Niu ZC, Han XL, et al. Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: a network pharmacology-integrated experimental study. J Ethnopharmacol. 2021; 270:113815.
|
| [10] |
Cai Z, Wang H, Jiang J, et al. Elaborate the mechanism of ancient classic prescriptions (Erzhi formula) in reversing GIOP by network pharmacology coupled with zebrafish verification. Evid Based Complement Alternat Med. 2022; 2022:7019792.
|
| [11] |
Zhu T, Chen W, Han C, et al. A comprehensive study on the chemical constituents and pharmacokinetics of Erzhi formula and Jiawei Erzhi formula based on targeted and untargeted LC-MS analysis. Curr Drug Metab. 2023; 23(14): 1130-1142.
|
| [12] |
Cummings SR, Santora AC, Black DM, Russell RGG. History of alendronate. Bone. 2020; 137:115411.
|
| [13] |
Harada A, Ito S, Matsui Y, et al. Effect of alendronate on muscle mass: investigation in patients with osteoporosis. Osteoporos Sarcopenia. 2015; 1(1): 53-58.
|
| [14] |
Chiu HC, Chiu CY, Yang RS, Chan DC, Liu SH, Chiang CK. Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. J Cachexia Sarcopenia Muscle. 2018; 9(3): 585-602.
|
| [15] |
Si M, Sun Q, Ding H, Huang M. Improvement effect of total saponins of dioscoreae nipponicae rhizoma on osteoporosis in ovariectomized model rats. China Pharm. 2022; 31(2): 57-61.
|
| [16] |
Lyu AK, Zhu SY, Chen JL, et al. Inhibition of TLR9 attenuates skeletal muscle fibrosis in aged sarcopenic mice via the p53/SIRT1 pathway. Exp Gerontol. 2019; 122: 25-33.
|
| [17] |
Yousefzadeh N, Kashfi K, Jeddi S, Ghasemi A. Ovariectomized rat model of osteoporosis: a practical guide. EXCLI J. 2020; 19: 89-107.
|
| [18] |
Drey M, Sieber CC, Bertsch T, Bauer JM, Schmidmaier R, FiAT Intervention Group. Osteosarcopenia is more than sarcopenia and osteopenia alone. Aging Clin Exp Res. 2016; 28(5): 895-899.
|
| [19] |
Tang Z, Lin S, Yang B, et al. Effects of Zhuanggu Qiangji decoction on skeletal muscle morphology and function in ovariectomized rats. Chin J Osteoporos. 2023; 29(4): 550-554+561.
|
| [20] |
Ferri E, Marzetti E, Calvani R, Picca A, Cesari M, Arosio B. Role of age-related mitochondrial dysfunction in sarcopenia. Int J Mol Sci. 2020; 21(15):5236.
|
| [21] |
Yokoyama S, Ohno Y, Egawa T, et al. MBNL1-associated mitochondrial dysfunction and apoptosis in C2C12 Myotubes and mouse skeletal muscle. Int J Mol Sci. 2020; 21(17):6376.
|
| [22] |
Zhao M, Wang Y, Li L, et al. Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance. Theranostics. 2021; 11(4): 1845-1863.
|
| [23] |
Chan DC. Mitochondrial dynamics and its involvement in disease. Annu Rev Pathol. 2020; 15: 235-259.
|
| [24] |
Genova ML, Lenaz G. Functional role of mitochondrial respiratory supercomplexes. Biochim Biophys Acta. 2014; 1837(4): 427-443.
|
| [25] |
Bouviere J, Fortunato RS, Dupuy C, Werneck-de-Castro JP, Carvalho DP, Louzada RA. Exercise-stimulated ROS sensitive signaling pathways in skeletal muscle. Antioxidants (Basel). 2021; 10(4):537.
|
| [26] |
Nikooie R, Moflehi D, Zand S. Lactate regulates autophagy through ROS-mediated activation of ERK1/2/m-TOR/p-70S6K pathway in skeletal muscle. J Cell Commun Signal. 2021; 15(1): 107-123.
|
| [27] |
Wang D, Yang Y, Zou X, Zhang J, Zheng Z, Wang Z. Antioxidant apigenin relieves age-related muscle atrophy by inhibiting oxidative stress and hyperactive mitophagy and apoptosis in skeletal muscle of mice. J Gerontol A Biol Sci Med Sci. 2020; 75(11): 2081-2088.
|
| [28] |
Gomes MJ, Martinez PF, Pagan LU, et al. Skeletal muscle aging: influence of oxidative stress and physical exercise. Oncotarget. 2017; 8(12): 20428-20440.
|
| [29] |
Katz A. A century of exercise physiology: key concepts in regulation of glycogen metabolism in skeletal muscle. Eur J Appl Physiol. 2022; 122(8): 1751-1772.
|
| [30] |
Judge A, Dodd MS. Metabolism. Essays Biochem. 2020; 64(4): 607-647.
|
| [31] |
Hargreaves M. Muscle glycogen and metabolic regulation. Proc Nutr Soc. 2004; 63(2): 217-220.
|
| [32] |
Armandi A, Rosso C, Caviglia GP, Ribaldone DG, Bugianesi E. The impact of dysmetabolic sarcopenia among insulin sensitive tissues: a narrative review. Front Endocrinol (Lausanne). 2021; 12:716533.
|
| [33] |
Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes. 2019; 12: 1057-1072.
|
| [34] |
Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016; 7(2): 126-135.
|
| [35] |
Reinders I, Murphy RA, Brouwer IA, et al. Muscle quality and myosteatosis: novel associations with mortality risk: the Age, Gene/Environment Susceptibility (AGES)-Reykjavik study. Am J Epidemiol. 2016; 183(1): 53-60.
|
| [36] |
Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017; 35: 200-221.
|
| [37] |
Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie. 2005; 87(1): 57-64.
|
| [38] |
Li M, Yang Y. Nucleotides and their application in the treatment of mitochondrial disorders. Chin J Pract Pediatr. 2023; 38(10): 754-758.
|
| [39] |
Nikolova-Karakashian MN, Reid MB. Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle. Antioxid Redox Signal. 2011; 15(9): 2501-2517.
|
| [40] |
Bruni P, Donati C. Pleiotropic effects of sphingolipids in skeletal muscle. Cell Mol Life Sci. 2008; 65(23): 3725-3736.
|
| [41] |
Seal A, Hughes M, Wei F, et al. Sphingolipid-induced bone regulation and its emerging role in dysfunction due to disease and infection. Int J Mol Sci. 2024; 25(5):3024.
|
| [42] |
Qi T, Li L, Weidong T. The role of sphingolipid metabolism in bone remodeling. Front Cell Dev Biol. 2021; 9:752540.
|
| [43] |
Khavandgar Z, Murshed M. Sphingolipid metabolism and its role in the skeletal tissues. Cell Mol Life Sci. 2015; 72(5): 959-969.
|
| [44] |
Grewe JM, Knapstein PR, Donat A, et al. The role of sphingosine-1-phosphate in bone remodeling and osteoporosis. Bone Res. 2022; 10(1): 34.
|
| [45] |
Binkley N, Krueger D, Buehring B. What's in a name revisited: should osteoporosis and sarcopenia be considered components of “dysmobility syndrome?” Osteoporos Int. 2013; 24(12): 2955-2959.
|
| [46] |
Livshits G, Gao F, Malkin I, et al. Contribution of heritability and epigenetic factors to skeletal muscle mass variation in United Kingdom twins. J Clin Endocrinol Metab. 2016; 101(6): 2450-2459.
|
| [47] |
Jiang Y, Liang J, Liu J, Wu Q, Min J. Mechanism of Erzhi pills in the treatment of postmenopausal osteoporosis based on OPG/RANK/RANKL signal axis. World Chin Med. 2022; 17(1): 92-97.
|
| [48] |
Han L, Tan D, Wan S, et al. The effect of Erzhiwan on glucose metabolism of adipose tissue in postmenopausal osteoporosis model rats. J Nanjing Univ Trad Chin Med. 2022; 38(5): 419-423+438.
|
Rights & permissions
2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
PDF
(4985KB)
